- Penumbra’s novel products and international-facing strategy put it on track to absorb the surging demand for minimally invasive vascular procedures.
- In 2021, Penumbra reported 33% year-over-year revenue gains, with international revenues from cardio and neuro products increasing by 53% and 33% respectively.
- I assign a Buy rating on the PEN stock. With a forward EBITDA growth rate that dwarfs its competitors, PEN is heading for significant appreciation in the next several quarters.
For further details see:
Penumbra Stock: A Medical Device Recovery Play With Strong Growth Potential